Pharmaceutical - Enbrel

Filter

Current filters:

Enbrel

Popular Filters

EXPERT VIEW: Strengthening market access through insight-driven real-world evidence

EXPERT VIEW: Strengthening market access through insight-driven real-world evidence

05-01-2015

Growing demand for access to health care alongside advances in science and technology has led to heightened…

EnbrelGlobalPharmaceuticalRegulationSenior Consulting

Mixed Ph III data for Pfizer’s tofacitinib vs Enbrel in plaque psoriasis

24-03-2014

US pharma giant Pfizer has announced detailed results from OPT Compare (A3921080), a Phase III study…

DermatologicalsEnbrelPfizerPharmaceuticalResearchtofacitinibXeljanz

Pfizer revenues down as patent losses hit sales

Pfizer revenues down as patent losses hit sales

29-10-2013

Global pharma giant Pfizer has said worldwide sales fell 2% to $12.6 billion, hurt by generic competition,…

AriceptEliquisEnbrelFinancialLipitorNorth AmericaPfizerPharmaceuticalRebifSpiriva

Generics triple-therapy just as effective as brand-name Enbrel, new study shows

13-06-2013

Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in…

AmgenAnti-Arthritics/RheumaticsEnbrelGenericsmethotrexatePharmaceuticalResearch

Steady sales for MAbs in rheumatoid arthritis - can biologics beat the patent cliff?

13-02-2013

Since 2004, the market for monoclonal antibodies (MAbs) in rheumatoid arthritis (RA) has experienced…

Anti-Arthritics/RheumaticsBiotechnologyEnbrelHumiraMarkets & MarketingPharmaceuticalRemicade

Takeda loses distribution of 13 Pfizer products in Japan

19-06-2012

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) has concluded an agreement that, as of December…

Asia-PacificBenefixEnbrelLicensingMarkets & MarketingPfizerPharmaceuticalPrevenarTakeda Pharmaceuticals

Back to top